1. Home
  2. COEP vs FAAS Comparison

COEP vs FAAS Comparison

Compare COEP & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • FAAS
  • Stock Information
  • Founded
  • COEP 2017
  • FAAS 2021
  • Country
  • COEP United States
  • FAAS Indonesia
  • Employees
  • COEP N/A
  • FAAS N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • FAAS
  • Sector
  • COEP Health Care
  • FAAS
  • Exchange
  • COEP Nasdaq
  • FAAS NYSE
  • Market Cap
  • COEP 32.4M
  • FAAS 34.6M
  • IPO Year
  • COEP N/A
  • FAAS N/A
  • Fundamental
  • Price
  • COEP $11.54
  • FAAS $0.60
  • Analyst Decision
  • COEP
  • FAAS
  • Analyst Count
  • COEP 0
  • FAAS 0
  • Target Price
  • COEP N/A
  • FAAS N/A
  • AVG Volume (30 Days)
  • COEP 136.7K
  • FAAS 431.5K
  • Earning Date
  • COEP 03-25-2025
  • FAAS 09-17-2024
  • Dividend Yield
  • COEP N/A
  • FAAS N/A
  • EPS Growth
  • COEP N/A
  • FAAS N/A
  • EPS
  • COEP N/A
  • FAAS N/A
  • Revenue
  • COEP N/A
  • FAAS $57,730,593.00
  • Revenue This Year
  • COEP N/A
  • FAAS N/A
  • Revenue Next Year
  • COEP N/A
  • FAAS N/A
  • P/E Ratio
  • COEP N/A
  • FAAS N/A
  • Revenue Growth
  • COEP N/A
  • FAAS 38.16
  • 52 Week Low
  • COEP $2.31
  • FAAS $0.38
  • 52 Week High
  • COEP $13.70
  • FAAS $12.97
  • Technical
  • Relative Strength Index (RSI)
  • COEP 59.40
  • FAAS 41.84
  • Support Level
  • COEP $8.65
  • FAAS $0.43
  • Resistance Level
  • COEP $13.70
  • FAAS $0.55
  • Average True Range (ATR)
  • COEP 2.11
  • FAAS 0.10
  • MACD
  • COEP -0.24
  • FAAS -0.01
  • Stochastic Oscillator
  • COEP 61.22
  • FAAS 19.95

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About FAAS DIGIASIA CORP

DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.

Share on Social Networks: